Skip to content

Enterprise value at other companies

Baxter International logo
Baxter InternationalBAX
$6.88B-55.6%
PTH
Pelthos Therapeutics Inc.PTHS
$68.17M
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$543.41M+96.3%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$16.77B+178%
RFL
Rafael Holdings, Inc.RFL
$52.06M+46.1%
Opko Health logo
Opko HealthOPK
$918.12M-21.5%

Other financials

Income statement

See full
Revenue$9.1M-22.0%
Gross profit$7.2M-30.0%
Operating income-$3.1M-342%
Net income-$3.3M-362%
EPS (diluted)-$0.22-375%

Balance sheet

See full
Cash & equivalents$11.0M-27.1%
Total debt$4.8M-7.1%
Total equity$21.6M-24.5%
Total assets$71.0M+1.5%

Cash flow

See full
Operating cash flow$387.0K-90.1%
CapEx--100%
Free cash flow$387.0K-89.9%

Valuation

See full
Market cap$97.09M+142%
P/S2.3×+1.4×

Profitability

See full
Gross margin82.9%-1.4pp
Operating margin-17.2%-125pp
Net margin-17.6%-103pp
FCF margin3.3%

Returns & leverage

See full
Return on equity-29.4%-86.3pp
Debt / equity0.2×0.0×
Current ratio-0.3×

Where this comes from

Calculated from Cumberland Pharmaceuticals’s reported figures.

The official record: Cumberland Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cumberland Pharmaceuticals's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cumberland Pharmaceuticals's enterprise value?
Cumberland Pharmaceuticals (CPIX) reported enterprise value of $42.43M in Q1 2026.
How has Cumberland Pharmaceuticals's enterprise value changed year-over-year?
Cumberland Pharmaceuticals's enterprise value decreased by 13.7% year-over-year, from $49.18M to $42.43M.
What is the long-term trend for Cumberland Pharmaceuticals's enterprise value?
Over 5 years (2020 to 2025), Cumberland Pharmaceuticals's enterprise value has grown at a 19.8% compound annual growth rate (CAGR), from $21.5M to $53.02M.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.